Hero image

Drug delivery technology

CP-012 combines a well-established treatment with a clinical tested drug-delivery technology. The innovation lies in the timing: the medicine is designed to be released and absorbed in the early morning hours , while the patient is still at sleep.

The CP-012 tablet

Active ingredients: levodopa and carbidopa.

Design: tablet-in-tablet - an inner core with the active ingredients, surrounded by an outer layer that controls when release starts.

Release profile: delayed, dual-pulse release designed to deliver carbidopa and levodopa in the late night and early morning.

Administration: taken orally at bedtime, in addition to usual Parkinson's medication.

Xxxxxxxx xxxxx

xxxxxx

Confirmed in clinical studies

Using pharmacoscintigraphy - a small radioactive marker that can be followed by a gamma camera - we have shown in both healthy volunteers and people with Parkinson's that CP-012 releases its content at the intended time several hours after bedtime dosing. This translates into the expected delayed levodopa levels in the blood.

The OralogiK™ technology

CP-012 is formulated using OralogiK™, a tablet-in-tablet drug-delivery platform developed by BDD Pharma (Glasgow, UK). OralogiK™ allows timed and targeted release of one or more drugs.